Merestinib clinical trials
Also written LY2801653.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses merestinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2016 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 2
Eli Lilly and Company (6) · Dana-Farber Cancer Institute (1) · University of Utah (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses merestinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract CancerActive, not recruitingPhase 2Eli Lilly and CompanyNCT02711553Written as Merestinib
- Merestinib In Non-Small Cell Lung Cancer And Solid TumorsTerminatedPhase 2Dana-Farber Cancer InstituteNCT02920996Written as Merestinib
- Merestinib on Bone Metastases in Subjects With Breast CancerTerminatedPhase 1University of UtahNCT03292536Written as Merestinib
- A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic CancerCompletedPhase 1Eli Lilly and CompanyNCT03027284Written as Merestinib
- A Study of LY2801653 in Advanced CancerCompletedPhase 1Eli Lilly and CompanyNCT01285037Written as LY2801653
- A Study of Merestinib (LY2801653) in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT02779738Written as Merestinib
- A Study of LY2801653 in Healthy Participants Who Are Not Able to Have ChildrenCompletedPhase 1Eli Lilly and CompanyNCT02370485Written as LY2801653
- A Study of LY2801653 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT01981408Written as [^14C]-LY2801653
Given beside what is tested · 3 — merestinib is usual care or a partner of the new treatment
- A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid TumorsCompletedPhase 1Eli Lilly and CompanyNCT02791334Written as Merestinib
- Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedPhase 1Jacqueline Garcia, MDNCT03125239Written as Merestinib
- A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted AgentsCompletedPhase 1Eli Lilly and CompanyNCT02745769Written as Merestinib
Codes
What other systems call merestinib · ClinicalTrials.gg INT006431
- MeSH (NLM) C586252merestinibOne source NLM
- UNII (FDA) 5OGS5K699EMERESTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27262653merestinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95729MerestinibOne source FDA
- DrugBank DB12381One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C586252 | merestinib | One source NLM |
| UNII (FDA) | 5OGS5K699E | MERESTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27262653 | merestinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95729 | Merestinib | One source FDA |
| DrugBank | DB12381 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.